| Prev Close | 121.00 |
| Day Low/High | 115.19 / 120.84 |
| 52 Wk Low/High | 120.68 / 197.00 |
| Avg Volume | 2.28M |
Allergan Plc (AGN)
115.92
NYSE : Health Technology
| Exchange | NYSE |
| Shares Outstanding | 327.80M |
| Market Cap | 39.66B |
| EPS | -15.30 |
| P/E Ratio | N/A |
| Div & Yield | 2.96 (2.39%) |
Latest News
Allergan Stock Slips Despite Beat and Raised Guidance
Shares of the maker of Botox are struggling despite its latest results exceeding expectations.
More Mud on Johnson & Johnson?
There's been enough news with the lawsuits around this name to get the emotion back into the stock. Emotion often leads to volatility.
Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot
In this day and age, companies must be 'disruptors' or get left in the dust.
Watching Shares of Och-Ziff Capital Management
With shares breaking above the recent, albeit small, pennant, there might be reason for optimism.
Activists Aim to Eliminate Dual Role for Allergan CEO Saunders
David Tepper's Appaloosa LP renews calls for changes at the top.
Jim Cramer: No Room for Cynicism, JNJ's New Depression Drug Is Lifesaving
The approval of esketamine, known as Spravato, for use against severe depression is special -- it is saving lives.
I Like These 2 Smaller Name Biotech Stocks
I still believe it will be a big year for buyouts across the biotech industry.
Evolus Stockholders May Be Frowning in the Short Run
Shares of the Botox competitor could correct/consolidate after a recent surge.
How Are My Ideas Working Out? January Trade Review (Part 2)
Clearly, the first half of the month shaped up better than the second half.
Sloppy Earnings, China's Economy, AMD Earnings Preview: Market Recon
What we have seen of late from a number of chip producers really might be interpreted as pre-recessionary.
Allergan Could Retest Its December Low Before a Better Rally Attempt
Allergan could move higher but some sort of retest of the December low seems in order in the short to intermediate term.
Jim Cramer: What Are We to Make of Today's Market Decline?
Is it a retest based on the damage the Fed has already done, the result of a breakdown in trade talks or a sign of a slowing global economy?
Jim Cramer: This Market Takes Its Cue From the Positive and Ignores the Negative
So far 2019 is proving to be a year where things have a habit of working out right.
Try This Allergan Two-Week Setup
The company is set to report earnings on Jan. 29, so traders have a couple of weeks to watch the action.
Allergan Must Prove Itself With Signs of More Aggressive Buying
A three-year decline in the shares of the maker of Botox will take more than a two-week bounce to reverse.
Real Money Post Industrial Average Outperformed the Market in 2018
The RMPIA index was up for the year, while the S&P 500, DJIA, Russell 2000 and Nasdaq all finished 2018 in the red.
The Charts of Allergan Look Very Bearish With New Lows Made Yesterday
When I looked at the charts this morning I found a stock that could still decline further.
Jim Cramer: My Take on These Companies Where Lawsuits Are Front and Center
These are currently situations where companies are facing serious lawsuits.
Allergan Needs to Rebase on the Charts - Don't Rush It
Let's check the charts and technical indicators for some guidance.
Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken
Once the safest stocks in the book, the big-cap drug companies are now toxic.
Staying Long Apple Into Tuesday's Product Launch: Market Recon
My target price and panic points have changed, and I am watching for a chance to add or shave some off, depending on which direction the stock takes.
Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter
Straying from these names could land you in quicksand as the 4th quarter begins.
A Bullish Options Play on Allergan
Buyout rumors aside, AGN is a name I still find attractive.
Allergan Has Finally Made a Base Pattern Traders Can Approach From the Long Side
Let's check out the charts again so see how far this advance might carry.
Jim Cramer: This Is a Rotation, Not a Recession
There's too much evidence of economic strength, so don't interpret these moves as a sign of a real slowdown.
